PlainRecalls
FDA Drug Moderate Class II Ongoing

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Reported: October 29, 2025 Initiated: October 21, 2025 #D-0097-2026

Product Description

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Reason for Recall

Lack of Assurance of Sterility.

Details

Units Affected
12,778 total vials
Distribution
Nationwide in the USA
Location
New Brunswick, NJ

Frequently Asked Questions

What product was recalled?
Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11. Recalled by Bristol-Myers Squibb Company. Units affected: 12,778 total vials.
Why was this product recalled?
Lack of Assurance of Sterility.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 29, 2025. Severity: Moderate. Recall number: D-0097-2026.